Inside Your Peptides — reports

BPC-157: The Evidence, Graded Honestly

Sat, 22 Aug 2026 09:00:00 +0000

The internet's favorite healing peptide rests almost entirely on rodent studies from one research cluster, with no published randomised human trials. What the animal data shows, what WADA and FDA have said, and where the honest uncertainty sits.

The Collagen, Elastin and Pore Report: 40 Interventions Ranked by Evidence, Not Marketing

Sat, 22 Aug 2026 09:00:00 +0000

We graded 40 topical, injectable and lifestyle interventions for skin collagen, elastin and pores against the actual human trial record. Two retractions, one negative copper-peptide trial nobody cites, and zero injectable peptides with a skin endpoint.

The GHK-Cu Report: 30 Routes, Products and Rivals Ranked by Evidence

Sat, 22 Aug 2026 09:00:00 +0000

GHK-Cu ranked route by route, then against the whole skin-aging field. The one randomised facial trial was null, and FDA excluded the injectable route by name.

GLP-1s and Muscle: How Much Lean Mass You Actually Lose

Sat, 22 Aug 2026 09:00:00 +0000

In STEP 1's DXA substudy, roughly 39% of the weight lost on semaglutide was lean mass. The SURMOUNT-1 substudy put tirzepatide's share near a quarter. What those numbers mean, what lean mass actually is, and the two counterweights with real evidence behind them.

How to Read a Peptide COA — the five measures that matter

Sat, 22 Aug 2026 09:00:00 +0000

Purity is one number on a certificate of analysis. Identity, net content, endotoxin, and microbial screening are the measures most peptide COAs quietly skip. How to read a certificate in five minutes — and catch a fake.

The Peptide Payment Problem: Why Your Card Gets Declined [and What a Crypto-Only Checkout Tells You]

Sat, 22 Aug 2026 09:00:00 +0000

Stripe, PayPal, and Square all prohibit research chemicals — so every peptide vendor runs on secondary payment rails. What each rail means for your chargeback rights, why checkout pages keep changing, and why a 10-15% crypto discount is the measured price of your protection.

The Politics of Peptides in 2026: FDA, Compounding, and the GLP-1 Turf War

Sat, 22 Aug 2026 09:00:00 +0000

The compounded GLP-1 market was created by shortage rules and is being unwound by them. How the shortage-list mechanism worked, what ended in 2025, where research-use-only vendors legally sit, and what to watch next — reported without hype.

Banned in Sport, Untested in Medicine: What Anti-Doping Actually Knows About Peptides

Sat, 22 Aug 2026 09:00:00 +0000

A WADA ban is not proof a peptide works — S0 bans by category. But sport has funded detection chemistry for compounds medicine will not fund a trial for. That asymmetry is the signal.

Retatrutide: What the Data Actually Shows [and What It Doesn't]

Sat, 22 Aug 2026 09:00:00 +0000

Everyone quotes the 24% weight-loss number. Almost nobody says it came from a phase 2 trial of 338 people over 48 weeks — for a molecule that is not approved. What the retatrutide data shows, what it can't show yet, and what the gray market does with the gap.

The State of Peptides, 2026: What They Are, Who Is Fighting Over Them, and What Each One Can Prove

Sat, 22 Aug 2026 09:00:00 +0000

What a peptide is, what changed in Washington in 2026, and seventeen catalogue compounds graded on human evidence. Two hold an approval. Seven grade D.

"Tested" Is Not One Thing: Sterility, Endotoxin, and What Certificates Actually Cover

Sat, 22 Aug 2026 09:00:00 +0000

Endotoxin testing, PCR microbial screens, and USP <71> sterility are three different tests that the market blurs into one word. What each method measures, what a pass means, and what a buyer of injectable-format compounds should actually demand.

The Community Evidence Layer: What a Million Self-Experimenters Have Actually Established

Sat, 22 Aug 2026 09:00:00 +0000

Between the empty clinical file and the marketing noise sits the largest uncontrolled experiment in modern self-medication. Five tiers of community evidence, ranked by what each one can actually establish.

The 2026 COA Audit: Peptide Vendors Graded on the Documents They Publish

Sat, 22 Aug 2026 09:00:00 +0000

We graded peptide vendors on one axis only: the quality documents they actually publish. Named labs, accession numbers, measured fill, five-measure panels — or nothing. The criteria are public and the disclosure is at the top.

Where US Peptide Vendors Actually Get Their Powder

Sat, 22 Aug 2026 09:00:00 +0000

Nearly every research peptide sold in the US starts as bulk API from overseas synthesizers. FDA Import Alert 66-80 now detains GLP-1 shipments by default — unless the maker is one of 19 green-listed firms worldwide. How the supply chain works, and how to check a supplier yourself.

The Orphan Molecule Problem: Why There Will Never Be a BPC-157 Trial

Sat, 22 Aug 2026 09:00:00 +0000

A phase 3 programme costs hundreds of millions and is repaid by exclusivity. BPC-157's sequence has been public since 1993. Nobody will ever fund the trial — and that is a market design, not a verdict.